Merck Reports Positive Trial Data for Pneumonia Vaccine in Younger Age Group.

Merck has announced positive late-stage trial data for its pneumonia vaccine, Capvaxive, showing it is effective in adults aged 2-18 years. The data, from a 30-day post-vaccination analysis of the Phase 3 trial, suggests that the vaccine prevents invasive pneumococcal disease and pneumonia in this age group. The results are promising for Merck, which is seeking to expand the use of Capvaxive to younger populations.